Filing Details

Accession Number:
0001144204-14-071685
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-01 19:50:27
Reporting Period:
2014-11-25
Filing Date:
2014-12-01
Accepted Time:
2014-12-01 19:50:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1597131 Glori Energy Inc. GLRI Crude Petroleum & Natural Gas (1311) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1605596 A Matthew Gibbs C/O Oxford Bioscience Partners
535 Boylston Street, Suite 402
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-11-25 19,560 $4.38 4,162,488 No 4 S Indirect Footnotes
Common Stock Disposition 2014-11-25 440 $4.38 4,162,048 No 4 S Indirect Footnotes
Common Stock Disposition 2014-11-26 19,560 $4.32 4,142,488 No 4 S Indirect Footnotes
Common Stock Disposition 2014-11-26 440 $4.32 4,142,048 No 4 S Indirect Footnotes
Common Stock Disposition 2014-11-28 1,500 $4.22 4,140,548 No 4 S Indirect Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Footnotes
No 4 S Indirect Footnotes
No 4 S Indirect Footnotes
No 4 S Indirect Footnotes
No 4 S Indirect Footnotes
Footnotes
  1. OBP Management V L.P. is the general partner of Oxford Bioscience Partners V L.P. ("Oxford") and mRNA Fund V L.P. ("mRNA"). After the above reported transactions, Oxford owns 4,049,256 of the referenced shares and mRNA owns 91,292 of the referenced shares. Matthew Gibbs is a general partner of OBP Management V L.P. All such entities, Mr. Gibbs disclaims beneficial ownership of such shares except to the extent of their pecuniary interests in such shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  2. These sales were of shares owned by Oxford.
  3. These sales were of shares owned by mRNA.